Device Trial Radar · NCT01979861
Safety & Effectiveness Study of AEGEA Vapor System to Treat Excessive Uterine Bleeding
Last checked: Nov 20, 2026Latest source record: Jul 12, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
230
Planned (sponsor's estimate)
Start
Feb 2014
Primary completion
Jun 2016
Study completion Jun 2018
Sponsor
- Lead sponsor
- Aegea Medical, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 8, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 30 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if the AEGEA Vapor System for endometrial ablation is safe and effective for reducing menstrual blood loss in women with excessive uterine bleeding (menorrhagia)
Conditions
- Menorrhagia
Interventions
AEGEA Vapor System(TM)Device
vapor endometrial ablation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Effectiveness EndpointTime frame: 12 months
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
Center for Fertility and Women's Health
New Britain, Connecticut
14 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.